Patents by Inventor Steven Mark Wenglowsky

Steven Mark Wenglowsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDK2 inhibitors
    Patent number: 11970498
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: February 8, 2023
    Date of Patent: April 30, 2024
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
  • CDK2 inhibitors
    Patent number: 11932648
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: June 27, 2022
    Date of Patent: March 19, 2024
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
  • CDK2 INHIBITORS
    Publication number: 20230322791
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: February 8, 2023
    Publication date: October 12, 2023
    Inventors: Douglas Wilson, Neil Bifulco, JR., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
  • CDK2 INHIBITORS
    Publication number: 20230159535
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: June 27, 2022
    Publication date: May 25, 2023
    Inventors: Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
  • Compounds and compositions useful for treating disorders related to NTRK
    Patent number: 11059827
    Abstract: This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: July 13, 2021
    Assignee: Blueprint Medicines Corporation
    Inventors: Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Joseph L. Kim
  • Compounds and compositions useful for treating disorders related to NTRK
    Patent number: 11046697
    Abstract: This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula (I):
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: June 29, 2021
    Inventors: Steven Mark Wenglowsky, Natasja Brooijmans, Chandrasekhar V. Miduturu, Neil Bifulco, Jr.
  • 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
    Patent number: 10774070
    Abstract: Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: September 15, 2020
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Natasja Brooijmans, Lucian V. DiPietro, Paul E. Fleming, Joseph L. Kim, Steven Mark Wenglowsky, Yulian Zhang
  • COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK
    Publication number: 20190382410
    Abstract: This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.
    Type: Application
    Filed: July 31, 2019
    Publication date: December 19, 2019
    Inventors: Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Joseph L. Kim
  • 2-(PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES AS RET INHIBITORS
    Publication number: 20190359591
    Abstract: Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g.
    Type: Application
    Filed: December 20, 2018
    Publication date: November 28, 2019
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Natasja BROOIJMANS, Lucian V. DIPIETRO, Paul E. FLEMING, Joseph L. KIM, Steven Mark WENGLOWSKY, Yulian ZHANG
  • Compounds and compositions useful for treating disorders related to NTRK
    Patent number: 10370379
    Abstract: This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula I:
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 6, 2019
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Jr., Joseph L. Kim
  • COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK
    Publication number: 20190169194
    Abstract: This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula (I):
    Type: Application
    Filed: July 3, 2018
    Publication date: June 6, 2019
    Inventors: Steven Mark WENGLOWSKY, Natasja Brooijmans, Chandrasekhar V. Miduturu, Neil Bifulco, JR.
  • 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
    Patent number: 10202365
    Abstract: Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: February 12, 2019
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Natasja Brooijmans, Lucian V. DiPietro, Paul E. Fleming, Joseph L. Kim, Steven Mark Wenglowsky, Yulian Zhang
  • Compounds and compositions useful for treating disorders related to NTRK
    Patent number: 10017512
    Abstract: This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula (I):
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: July 10, 2018
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Steven Mark Wenglowsky, Natasja Brooijmans, Chandrasekhar V. Miduturu, Neil Bifulco, Jr.
  • Compositions useful for treating disorders related to kit
    Patent number: 9994552
    Abstract: Compounds and compositions useful for treating disorders related to Kit are described herein.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: June 12, 2018
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Lucian V. DiPietro, Brian L. Hodous, Joseph L. Kim, Chandrasekhar V. Miduturu, Steven Mark Wenglowsky, Douglas Wilson, Yulian Zhang
  • 2-(PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES AS RET INHIBITORS
    Publication number: 20180022731
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: February 5, 2016
    Publication date: January 25, 2018
    Inventors: Natasja Brooijmans, Lucian V. DiPietro, Paul E. Fleming, Joseph L. Kim, Steven Mark Wenglowsky, Yulian Zhang
  • COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK
    Publication number: 20170145018
    Abstract: This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.
    Type: Application
    Filed: November 18, 2016
    Publication date: May 25, 2017
    Inventors: Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, JR., Joseph L. Kim
  • COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK
    Publication number: 20170066773
    Abstract: This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.
    Type: Application
    Filed: August 26, 2016
    Publication date: March 9, 2017
    Inventors: Steven Mark Wenglowsky, Natasja Brooijmans, Chandrasekhar V. Miduturu, Neil Bifulco, JR.
  • COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT
    Publication number: 20170029409
    Abstract: Compounds and compositions useful for treating disorders related to Kit are described herein.
    Type: Application
    Filed: October 17, 2016
    Publication date: February 2, 2017
    Inventors: Lucian V. DiPietro, Brian L. Hodous, Joseph L. Kim, Chandrasekhar V. Miduturu, Steven Mark Wenglowsky, Douglas Wilson, Yulian Zhang
  • Compositions useful for treating disorders related to kit
    Patent number: 9499522
    Abstract: Compounds and compositions useful for treating disorders related to Kit are described herein.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 22, 2016
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Lucian V. DiPietro, Brian L. Hodous, Joseph L. Kim, Chandrasekhar V. Miduturu, Steven Mark Wenglowsky, Douglas Wilson, Yulian Zhang
  • Serine/threonine kinase inhibitors
    Patent number: 9133187
    Abstract: Compounds having the formula I wherein Z, Z1 Z2 Z3, R3a, R3b and Rb and as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: September 15, 2015
    Assignees: ARRAY BIOPHARMA INC., GENENTECH, INC.
    Inventors: James F. Blake, Huifen Chen, Mark Joseph Chicarelli, Jason Demeese, Rustam Garrey, John J. Gaudino, Robert J. Kaus, Gabrielle R. Kolakowski, Allison L. Marlow, Peter J. Mohr, Li Ren, Jacob Schwarz, Christopher S. Siedem, Allen A. Thomas, Eli Wallace, Steven Mark Wenglowsky, Steven Boyd